Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 11/20 | 0.57 |
| ▸ | AXL | P30530 | 3/20 | 0.55 |
| ▸ | CRBN | Q96SW2 | 8/20 | 0.54 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.54 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL464519 | 0.94 | CRBN (0.60) | BRD4CRBNDDB1MAP1LC3B | |
| SCHEMBL22464461 | 0.94 | CRBN (0.60) | BRD4CRBNDDB1MAP1LC3B | |
| SCHEMBL29137874 | 0.93 | CRBN (0.59) | BRD4CRBNDDB1MAP1LC3B | |
| SCHEMBL22464808 | 0.93 | CRBN (0.59) | BRD4CRBNDDB1MAP1LC3B | |
| SCHEMBL20362334 | 0.93 | CRBN (0.59) | BRD4CRBNDDB1MAP1LC3B | |
| SCHEMBL23772949 | 0.93 | CRBN (0.59) | BRD4CRBNDDB1MAP1LC3B | |
| SCHEMBL22075921 | 0.92 | BRD4 (0.58) | BRD4AXLCRBNDDB1MAP1LC3B | |
| SCHEMBL26321010 | 0.90 | CRBN (0.64) | BRD4CRBNDDB1MAP1LC3B | |
| SCHEMBL26321021 | 0.90 | CRBN (0.64) | BRD4CRBNDDB1MAP1LC3B | |
| SCHEMBL21062843 | 0.90 | BRD4 (0.58) | BRD4CRBNDDB1MAP1LC3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691984-B2 | Compounds and methods for DCAF-mediated protein degradation | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-07-04 | — | — | US | disclosed |
| US-11691984-B2 | Compounds and methods for DCAF-mediated protein degradation | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-07-04 | — | — | US | disclosed |
| US-11691984-B2 | Compounds and methods for DCAF-mediated protein degradation | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-07-04 | — | — | US | disclosed |
| EP-3864030-A1 | COMPOUNDS AND METHODS FOR DCAF-MEDIATED PROTEIN DEGRADATION | The Scripps Research Institute (US) | 2021-08-18 | — | — | EP | disclosed |
| US-20200190105-A1 | COMPOUNDS AND METHODS FOR DCAF-MEDIATED PROTEIN DEGRADATION | THE SCRIPPS RESEARCH INSTITUTE | 2020-06-18 | — | — | US | disclosed |
| US-20200190105-A1 | COMPOUNDS AND METHODS FOR DCAF-MEDIATED PROTEIN DEGRADATION | THE SCRIPPS RESEARCH INSTITUTE | 2020-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190105-A1 | COMPOUNDS AND METHODS FOR DCAF-MEDIATED PROTEIN DEGRADATION | DCAF1, CUL4A, DCAF15 | BRD4 153/4885AXL 3344/4885CRBN 26/4885 |
| US-11691984-B2 | Compounds and methods for DCAF-mediated protein degradation | DCAF1, CUL4A, DCAF15 | BRD4 153/4885AXL 3344/4885CRBN 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.